Literature DB >> 29880714

Pharmacogenomics of antioxidant supplementation to prevent age-related macular degeneration.

Andrew J Vickers1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29880714      PMCID： PMC6016817          DOI： 10.1073/pnas.1803536115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  5 in total

1.  Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis.

Authors:  Johanna M Seddon; Rachel E Silver; Bernard Rosner
Journal:  Br J Ophthalmol       Date:  2016-07-28       Impact factor: 4.638

2.  Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration: Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study.

Authors:  Melissa J Assel; Fan Li; Ying Wang; Andrew S Allen; Keith A Baggerly; Andrew J Vickers
Journal:  Ophthalmology       Date:  2017-10-09       Impact factor: 12.079

3.  No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38.

Authors:  Emily Y Chew; Michael L Klein; Traci E Clemons; Elvira Agrón; Rinki Ratnapriya; Albert O Edwards; Lars G Fritsche; Anand Swaroop; Gonçalo R Abecasis
Journal:  Ophthalmology       Date:  2014-06-26       Impact factor: 12.079

4.  CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration.

Authors:  Carl C Awh; Anne-Marie Lane; Steven Hawken; Brent Zanke; Ivana K Kim
Journal:  Ophthalmology       Date:  2013-08-21       Impact factor: 12.079

5.  CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation.

Authors:  Demetrios G Vavvas; Kent W Small; Carl C Awh; Brent W Zanke; Robert J Tibshirani; Rafal Kustra
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205
  5 in total
  2 in total

1.  Reply to Vickers: Pharmacogenetics and progression to neovascular age-related macular degeneration-Evidence supporting practice change.

Authors:  Demetrios G Vavvas; Kent W Small; Carl Awh; Brent W Zanke; Robert J Tibshirani; Rafal Kustra
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-07       Impact factor: 11.205

2.  Novel Epigenetic Clock Biomarkers of Age-Related Macular Degeneration.

Authors:  Saurav Mallik; Fran Grodstein; David A Bennett; Demetrios G Vavvas; Bernardo Lemos
Journal:  Front Med (Lausanne)       Date:  2022-06-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.